The first group of domestic surgical robot radical resection of prostate cancer by Peking University First Hospital was published in the top international journal

In May 2022, the team of Prof. Cheng Chen, Prof. Xuesong Li and Prof. Liqun Zhou from the Department of Urology of Peking University First Hospital cooperated with Suzhou KangDuo Robot Co., LTD. (a subsidiary of Sagebot) to explore the clinical application of domestic laparoscopic surgical robot system in radical prostatectomy. The Paper named “Robot-assisted radical prostatectomy using the KangDuo Surgical Robot-01 system: a prospective, single-center, single-arm clinical study "is published online in the Journal of Urology, the official journal of the American Urological Association. The results suggested that the domestic KangDuo laparoscopic surgical robot system is safe and effective for radical prostatectomy.

Journal of Urology, founded in 1917, is the official journal of the American Urological Association (AUA). Its continuous publication of more than 100 years is the most famous, making it a widely read and highly cited professional journal in the world. It's one of the top journals in urology. As the first group of studies related to the domestic laparoscopic surgical robot system published in the official journal of the American Urological Association, it represents a high degree of recognition for the clinical application of China's domestic surgical robot system by western academia, led by the Da Vinci surgical robot system imported from the United States.

In recent years, the incidence of prostate cancer increased year by year in our country, and it became the first among elderly men over 70 years-old malignant tumors. Radical prostatectomy is one of the most effective treatments for organ-limited and locally advanced prostate cancer. With the continuous innovation of medical equipment, this procedure has undergone the transformation from open surgery to laparoscopic surgery to robot-assisted laparoscopic surgery. Radical prostatectomy requires complex operations such as free resection and suture reconstruction in the narrow pelvic cavity. Robot-assisted laparoscopic surgery system has a good field of vision and flexible operating experience, so it has significant advantages in radical prostatectomy. Over the past 20 years, Da Vinci laparoscopic surgical Robot System has dominated the global surgical robot market, but its high acquisition and maintenance costs have limited its wide application in China.

This is an exploratory single-center prospective single-arm cohort study to evaluate the safety and effectiveness of the domestic KangDuo laparoscopic surgical robot system developed by Suzhou KangDuo Robotic Co., Ltd. in the application of radical prostatectomy. A total of 16 patients were enrolled in this study, with a median age of 66 years and a median prostate volume of 39 ml. All operations were successfully completed, with a median robotic arm docking time of 5.9 minutes, a median robotic arm operation time of 87 minutes, and a median postoperative hospital stay of 5 days. No related complications were found during the follow-up period, and the short-term follow-up treatment effect was good. The urine control rate was 87.5% in 1 month after catheter removal. The team will continue to follow the patients to evaluate the long-term outcome of the surgery.

Domestic KangDuo laparoscopic surgical robot system

(A) The surgeon performs the operation in front of the console of the laparoscopic surgical robot system

(B) The assistant physician assisted at the operating table

In order to further scientifically evaluate the safety and effectiveness of domestic robotic laparoscopic surgery system for radical prostatectomy, a multi-center prospective randomized controlled study of domestic robotic laparoscopic surgery system for radical prostatectomy is currently underway, which is jointly promoted by the Department of Urology, Peking University First Hospital and the Department of Urology, Peking Union Medical College Hospital. Further research progress will be reported in the future.

Surgery robot , the representative of the high-end medical equipment ,has become related to people's life safety and health of the "national instrument". International market of surgery robot and even domestic market share has been monopolized by international giants. Under the current background, it has become a top priority to speed up the improvement of the shortcomings of China's high-end medical equipment and realize the autonomy and control of high-end medical equipment. The Institute of Urology, Peking University First Hospital, as one of the first cooperative units in the development of domestic laparoscopic robot, has completed the first randomized controlled trial of 100 cases of single operation and imported products in the world. The statistical results of relevant clinical trial data suggest that compared with the imported Da Vinci surgical robot in the United States, there is no statistical difference in the success rate of surgery and the main indicators. There were no device-related adverse events or surgical complications, and will receive NMPA registration in the near future. The research and development and application of domestic laparoscopic surgical robot system can break the absolute monopoly of original imported products in the high-end medical equipment market, inject new vitality into the market competition, make the robot surgery towards the direction of cost-effective development, and provide a good platform for the application of remote control, artificial intelligence, augmented reality and other technologies in surgery.

Article link：https://www.auajournals.org/doi/10.1097/JU.0000000000002498